- Short communication
- Open Access
[111In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery
© Schottelius et al. 2015
- Received: 23 September 2015
- Accepted: 17 November 2015
- Published: 25 November 2015
The relevance of prostate-specific membrane antigen (PSMA) targeting in the clinical management of prostate cancer (PCa) is continually increasing, entailing the development of PSMA-targeted molecular probes. Recently, a first PSMA-targeted theranostic concept has been successfully implemented by [68Ga/177Lu]PSMA-I&T. To further exploit the excellent PSMA-targeting characteristics and in vivo performance of the PSMA-I&T platform, [111In]PSMA-I&T was evaluated as a complementary probe for radioguided surgery and SPECT imaging.
Compared to [68Ga/177Lu]PSMA-I&T, [111In]PSMA-I&T showed unchangedly high PSMA-affinity and enhanced internalization into PSMA-expressing LNCaP PCa cells. Biodistribution studies in LNCaP xenograft-bearing mice (1 h p.i.) revealed slightly reduced background accumulation of [111In]PSMA-I&T compared to [177Lu]PSMA-I&T and identical tumor uptake of both compounds, leading to increased tumor/background ratios for [111In]PSMA-I&T. An exemplary patient with metastatic PCa underwent preoperative [68Ga]HBED-CC-PSMA PET/CT (1 h p.i.) and [111In]PSMA-I&T SPECT/CT (4 h p.i.), followed by prostatectomy and radioguided extended pelvic lymphadenectomy (24 h p.i.). In [111In]PSMA-I&T SPECT/CT, the previously identified PCa lesions ([68Ga]HBED-CC-PSMA PET/CT) showed high tracer accumulation and were also detectable using planar scintigraphy. The intraoperative use of a hand-held gamma probe allowed detection and resection of all [111In]PSMA-I&T-accumulating lesions. The presence of PSMA-positive tumor tissue in the resected specimens was confirmed histopathologically and via [111In]PSMA-I&T autoradiography.
[111In]PSMA-I&T shows efficient PSMA targeting in vitro and in vivo, combined with low background accumulation. In an exemplary PCa patient, [111In]PSMA-I&T was successfully applied for preoperative SPECT/CT visualization and radioguided resection of PSMA-positive lesions, hinting towards a high value of [111In]PSMA-I&T as a complementary tool to [68Ga/177Lu]PSMA-I&T in the clinical management of prostate cancer.
- Prostate-specific membrane antigen
- Targeted radionuclide therapy
- Radioguided surgery
Modern clinical management of prostate cancer increasingly relies on exploiting the prostate-specific membrane antigen (PSMA) as a molecular target both for imaging and for treatment of prostate cancer (PCa). PSMA is abundantly expressed on the surface of prostate cancer cells and within the neovasculature of other solid tumors, with limited expression in most normal tissues, establishing the basis for selective targeting of PCa lesions with PSMA-targeted agents. Among the rapidly increasing number of high-affinity PSMA ligands, ranging from intact antibodies to low-molecular-weight compounds, urea-based inhibitors have been most extensively leveraged, with expanding clinical use .
Recently, a successful theranostic concept has been realized by the development of [68Ga/177Lu]PSMA-I&T . Compared to first DOTA-conjugated EuK(=Glu-urea-Lys)-based inhibitors , the DOTAGA-conjugate PSMA-I&T has been optimized with respect to PSMA affinity and in vivo stability [2, 4]. First patient studies have demonstrated excellent PSMA targeting for [68Ga/177Lu]PSMA-I&T, permitting high-contrast PET imaging of metastatic PCa with [68Ga]PSMA-I&T and, based on suitable uptake and retention characteristics, efficient treatment with its therapeutic analog [177Lu]PSMA-I&T [5, 6].
PSMA affinities, internalization, and lipophilicity of In-, Ga-, and Lu-PSMA-I&T
Internalization [% of reference]
Lipophilicity [log POW]
7.5 ± 1.5
104 ± 7
9.4 ± 2.9
59 ± 2
7.9 ± 2.4
76 ± 2
As anticipated, [natIn]PSMA-I&T shows unchangedly high PSMA affinity in a competitive binding assay (IC50), which equals that of its natLu-counterpart. Unexpectedly, however, internalization efficiency of [111In]PSMA-I&T into LNCaP prostate cancer cells was found to be markedly enhanced compared to [177Lu]PSMA-I&T (Table 1).
Besides high tumor uptake, [111In]PSMA-I&T also shows significant accumulation in tissues with endogenous PSMA expression, i.e., lung and in particular kidney and spleen (Fig. 1). For the latter two organs, the substantially increased [111In]PSMA-I&T uptake is not the result of altered targeting characteristics of the tracer compared to [177Lu]PSMA-I&T, but is rather caused by the use of alternative mouse strains for the comparative evaluation of both compounds (CB17 SCID mice for [111In]PSMA-I&T vs CD1 nu/nu mice for [177Lu]PSMA-I&T). Particularly high tracer uptake in spleen and kidney in CB17 SCID mice has been consistently observed in the evaluation of a variety of PSMA-targeted radiopharmaceuticals in our lab and is mouse-strain specific.
In contrast, the accelerated blood clearance and reduced background accumulation of [111In]PSMA-I&T, especially in liver and intestines, are tracer specific. Due to its reduced lipophilicity compared to [68Ga]PSMA-I&T and [177Lu]PSMA-I&T (see Table 1), hepatobiliary excretion is further reduced in favor of almost exclusive renal excretion. Consequently, [111In]PSMA-I&T shows improved tumor(t)-to-background ratios compared to [177Lu]PSMA-I&T at 1 h p.i., i.e., t/blood-, t/liver-, t/intestines-, and t/muscle-ratios of 34 ± 8, 32 ± 6, 53 ± 8, and 43 ± 6, respectively, versus 18 ± 9, 7 ± 3, 12 ± 3, and 14 ± 9 for [177Lu]PSMA-I&T.
One day prior to surgery, the patient was injected with 155 MBq [111In]PSMA-I&T, and preoperative planar scintigraphy as well as SPECT/CT were performed at 4 h p.i. (Fig. 3b, e, h). Radical prostatectomy as well as radioguided lymphadenectomy using a hand-held gamma probe with visual and acoustic feedback (Crystal Probe CXS-SG603; Crystal Photonics, Berlin, Germany) were performed 24 h after injection of [111In]PSMA-I&T. The presence of PSMA-positive tumor tissue in the resected specimens was confirmed histopathologically and via [111In]PSMA-I&T autoradiography (Fig. 3i, j).
Ventral and dorsal views of whole body planar scintigraphy (Fig. 3b) show intense [111In]PSMA-I&T uptake in the primary tumor (solid arrows) as well as in pelvic and retroperitoneal lymph node metastases (dotted arrows). Axial [111In]PSMA-I&T SPECT/CT images confirm the intense tracer accumulation, both in the primary tumor (Fig. 3e) and in a representative morphologically not enlarged lymph node (Fig. 3h) and are consistent with [68Ga]HBED-CC PSMA PET/CT findings (Fig. 3d, g). During subsequent prostatectomy and salvage lymphadenectomy, the intraoperative use of a gamma probe allowed the detection and quantitative resection of all lymph nodes with [111In]PSMA-I&T accumulation. All resected lesions showing tracer uptake were histopathologically confirmed to be metastatic PCa deposits. Within the prostate, ex vivo autoradiography 4 h after surgery showed moderate to intense [111In]PSMA-I&T uptake in several intraprostatic tumor foci (I) correlating well with a H&E stained slide from histopathology (J), demonstrating the sensitive detection of PSMA-expressing tumor cells by [111In]PSMA-I&T.
Based on these initial promising results, the concept of radioguided lymphadenectomy in early recurrent prostate cancer patients using [111In]PSMA-I&T as a PSMA-targeted intraoperative probe has recently been further pursued [10, 11]. In a small cohort of patients, [111In]PSMA-I&T radioguided surgery was shown to represent a valuable technique for the intraoperative detection of small subcentimeter metastatic lymph nodes and atypically located lesions.
Additionally, [111In]PSMA-I&T showed promising in vivo characteristics as a PSMA-targeted SPECT imaging probe, including suitable whole-body clearance, predominant renal excretion, and efficient accumulation in PSMA-expressing tissues. Of course, in a direct comparison, [68Ga]HBED-CC PSMA PET/CT appears as the clearly superior imaging modality compared to [111In]PSMA-I&T SPECT/CT. However, this comparison is strongly biased in favor of [68Ga]HBED-CC PSMA PET/CT due to the inherent instrumental differences between PET and SPECT with respect to sensitivity and resolution. Furthermore, the comparably high gamma energy of 111In further challenges spatial resolution of [111In]PSMA-I&T SPECT/CT.
However, the present preclinical and first clinical data underline the suitability of PSMA-I&T as a versatile labeling platform for a variety of PSMA-targeted applications in nuclear oncology and urology, ranging from PET and SPECT to endoradiotherapy and radioguided surgery, encouraging the ongoing further investigation of [68Ga]PSMA-I&T, [177Lu]PSMA-I&T, and [111In]PSMA-I&T as valuable tools for their respective dedicated application.
The authors thank Alexandra Bartel, Simone Loher, and Sven Hintze for their excellent technical assistance. Furthermore, the authors thank Gregor Weirich for performing the histophathological analysis of the resected tissues. The current study was financially supported by the Deutsche Forschungsgemeinschaft (SFB824; subproject Z1).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Kiess A, Banerjee S, Mease R, Rowe S, Rao A, Foss C, et al. Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging. 2015;59:241–68.PubMedGoogle Scholar
- Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. Ga-68- and Lu-177-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56:1169–76.View ArticlePubMedGoogle Scholar
- Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Green G, Fox JJ, et al. Ga-68-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010;53:5333–41.PubMed CentralView ArticlePubMedGoogle Scholar
- Weineisen M, Simecek J, Schottelius M, Schwaiger M, Wester HJ. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res. 2014;4(1):63.PubMed CentralView ArticlePubMedGoogle Scholar
- Kulkarni H, Baum R, Weineisen M, Wester H, Schuchardt C, Wiessalla S, et al. Therapy of metastasized castrate-resistant prostate cancer using Lu-177 labeled DOTAGA-PSMA small molecules: first clinical results in a larger patient cohort. J Nucl Med. 2015;56(supplement 3):10.Google Scholar
- Baum R, Kulkarni H, Volkmer B, Bohuslavizki K, Schuchardt C, Klette I, et al. Theranostics of metastatic prostate cancer applying 177Lu PSMA small molecules in combination with Ga-68 PSMA PET/CT. Nuklearmediziner. 2015;38:145–52.View ArticleGoogle Scholar
- Bernhard C, Moreau M, Lhenry D, Goze C, Boschetti F, Rousselin Y, et al. DOTAGA-anhydride: a valuable building block for the preparation of DOTA-like chelating agents. Chem Eur J. 2012;18:7834–41.View ArticlePubMedGoogle Scholar
- Eder M, Schafer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, et al. Ga-68-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconj Chem. 2012;23:688–97.View ArticleGoogle Scholar
- Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid (68)Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–74.View ArticlePubMedGoogle Scholar
- Maurer T, Weirich G, Schottelius M, Weineisen M, Frisch B, Okur A, et al. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol. 2015;68:530–4.View ArticlePubMedGoogle Scholar
- Frisch B, Maurer T, Okur A, Weineisen M, Schottelius M, Kubler H, et al. Freehand SPECT for In-111-PSMA-I&T radioguided lymphadenectomy in prostate cancer patients. J Nucl Med. 2015;56(supplement 3):157.Google Scholar